Biocon Biologics and Viatris Receive European Commission Approval for Abevmy (biosimilar- bevacizumab)
Shots:
- The EC has approved the Abevmy (100 & 400mg) for the treatment in metastatic colorectal carcinoma- metastatic breast cancer- NSCLC- glioblastoma- ovarian- cervical- and renal cancer as part of a specific regimen
- The approval follows CHMP’s positive opinion and is valid in all EU Member States as well as in the EEA countries Iceland- Liechtenstein- and Norway
- The approval will strengthen Biocon’s portfolio of biosimilars for cancer in the EU- which include biosimilar Trastuzumab and biosimilar Pegfilgrastim
Ref: Biocon | Image: Medicircle
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com